New Horizons in the Treatment and Management of Multiple Sclerosis:

Best Practices for Improved Patient Outcomes

New Horizons in the Treatment and Management of Multiple Sclerosis is a 7-part
 series that will provide attendees with the latest information in MS management.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 7 or in order. These are archives
of live webinars held between December 7, 2016 and February 1, 2017. 

Each session has its own specific valid dates

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

The series is supported by educational grants from AbbVie, Bayer HealthCare, Biogen, Novartis Pharmaceuticals and Sanofi Genzyme.

 Description: Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. This multi-part webinar program will focus on novel mechanisms of action, managing relapse and switching therapy, autoinjectors, oral therapies and dosing and administration in MS, what is on the horizon in MS management, insights on the interplay of B cells and T cells in therapeutic MS management, and what managed care needs to know in the evolving management of MS. It is critical that HCPs who will be in attendance for the live seven part webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.
 



 
New Horizons in the Treatment and Management of Multiple Sclerosis: Exploring Novel Mechanisms of Action in the Treatment of MS
  • Examine key findings related to the mechanisms of action of emerging and new disease-modifying therapies
  • Analyze new pathways and mechanisms of action in the treatment and management of MS
  • Review newly approved therapies and therapies that are currently undergoing clinical trials and regulatory review that have novel mechanisms of action in MS management
Physician, Nursing and CMCN credits valid to December 31, 2018
 
Oral Therapies, Autoinjectors and Dosing/Administration in the Changing MS Management Paradigm: Overcoming Barriers to Treatment
  • Discuss barriers to treatment in management multiple sclerosis and strategies to overcome those barriers
  • Analyze the role of autoinjectors in the management of relapsing MS and discuss which patients could benefit from their use
  • Discuss oral therapies and their effect on MS efficacy and patient adherence in MS
  • Examine how dosing and administration of new therapies can affect patient adherence and outcomes
Physician, Nursing and CMCN credits valid to March 31, 2019
 

What’s on the Horizon in MS: A Review of Novel Therapies and Emerging Approaches

  • Review data and information from recent global and national MS annual meetings about the future of MS management and treatment
  • Analyze recent data from clinical trials on emerging and recently approved treatments
  • Compare and contrast novel mechanisms of action in emerging therapies and identify patients who might benefit from each type
  • Discuss possible changes to MS management over the course of the next year and how they might affect clinicians and managed care professionals
Physician, Nursing and CMCN credits valid to March 31, 2019
 

What’s on the Horizon in MS: What Managed Care Needs to Know in the Evolving Management of MS

  • Discuss methods to enable optimal cost management of both current and emerging disease-modifying therapy to be realized by multiple MS stakeholders including managed care organizations
  • Analyze strategies used by managed care organizations to facilitate high quality care for members with MS
  • Discuss how emerging therapies that are currently undergoing regulatory review and late stage clinical trials will affect managed care professionals in the multiple sclerosis arena
Physician, Nursing and CMCN credits valid to March 31, 2019
 

New Horizons in the Treatment and Management of Multiple Sclerosis: The Role of Vitamin D in Multiple Sclerosis Pathology and Treatment

  • Discuss immunoregulatory and neuroprotective mechanisms of vitamin D in multiple sclerosis (MS)
  • Summarize findings from observational and interventional studies of vitamin D in MS susceptibility and clinical outcomes
  • Examine and share knowledge about vitamin D into the broader therapeutic approach to managing patients with MS
Physician, Nursing and CMCN credits valid to March 31, 2019

Managing Relapse in MS – Strategies for Switching Therapy after Inadequate Response to Previous Treatment Regimens

  • Discuss key recent data on the efficacy and safety of current and emerging therapies for relapsing MS
  • Review patient, disease, and treatment characteristics that factor into relapsing MS treatment selection and considerations for predicting treatment response and identifying when to switch therapies
  • Review the role of teriflunomide and alemtuzumab in the management of relapsing MS
  • Discuss the role of interferon beta-1b in the management of relapsing MS
Physician, Nursing and CMCN credits valid to December 31, 2018

Insights on the Interplay of B cells and T cells in Therapeutic MS Management

  • Discuss the pathophysiology of MS as it relates to T- and B-cell behavior and mechanisms of action of MS therapies
  • Review recent clinical trial data on newer and investigative disease-modifying therapies (DMTs) for MS that act to deplete T- and/or B-cell populations to modulate or “reset” immune function in relapsing MS and Primary Progressive MS
  • Examine the integration of emerging therapies that are designed to selectively target CD20-positive B cells into the current treatment paradigm
  • Review adverse event strategies as they relate to emerging therapies that are designed to selectively target CD20-positive B cells
Physician, Nursing and CMCN credits valid to December 31, 2018